Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (referred to in metadata as Chemomab Therapeutics Ltd.) covers the month of July 2019. The report details the outcomes of the Company's 2019 Annual General Meeting of Shareholders held on July 2, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and shareholder voting results rather than financial performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The filing serves as a follow-up to a previous Form 6-K dated May 28, 2019, to announce the final results of shareholder proposals.
Management Commentary and Corporate Actions
Shareholders approved the following proposals at the Annual General Meeting:
- Proposal 1: Re-election of the Board of Directors, including Dr. Frank Haluska, Dr. Stephen Hoffman, Mr. Robert Connelly, Mr. Reginald Hardy, Dr. Lawrence Howard, Mr. Isaac Kohlberg, and Mr. Dennison Veru.
- Proposal 2: Approval of the compensation package for the Company's directors.
- Proposal 3: Approval of the compensation package for CEO Dr. Frank Haluska.
- Proposal 4: Approval of an amended Compensation Policy.
- Proposal 5: Re-appointment of Somekh Chaikin, Certified Public Accountants (Isr.), a member firm of KPMG International, as the independent registered public accounting firm for the year ending December 31, 2019.
Investor Verification Checklist
- Verify the specific terms of the amended Compensation Policy approved under Proposal 4.
- Confirm the exact compensation amounts for the Board and CEO as detailed in the proxy statement referenced in the filing.
- Review the Company's most recent Form 20-F or financial statements for actual revenue and cash flow data, as this filing contains none.
- Monitor the Company's pipeline updates, as this filing contains no operational or clinical trial progress.